JP2014510094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510094A5 JP2014510094A5 JP2014500486A JP2014500486A JP2014510094A5 JP 2014510094 A5 JP2014510094 A5 JP 2014510094A5 JP 2014500486 A JP2014500486 A JP 2014500486A JP 2014500486 A JP2014500486 A JP 2014500486A JP 2014510094 A5 JP2014510094 A5 JP 2014510094A5
- Authority
- JP
- Japan
- Prior art keywords
- sustained release
- dosage form
- pharmaceutical dosage
- solid oral
- oral pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013268 sustained release Methods 0.000 claims 68
- 239000012730 sustained-release form Substances 0.000 claims 68
- 239000002552 dosage form Substances 0.000 claims 56
- 239000000203 mixture Substances 0.000 claims 52
- 239000007787 solid Substances 0.000 claims 46
- 238000009472 formulation Methods 0.000 claims 27
- 239000011159 matrix material Substances 0.000 claims 27
- -1 vegitramide Chemical compound 0.000 claims 24
- 239000013543 active substance Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 17
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 13
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 13
- 238000000518 rheometry Methods 0.000 claims 13
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 11
- 229960000240 hydrocodone Drugs 0.000 claims 11
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 11
- 239000000014 opioid analgesic Substances 0.000 claims 10
- DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 claims 7
- 229960002738 hydromorphone hydrochloride Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 claims 6
- 229960002764 hydrocodone bitartrate Drugs 0.000 claims 6
- 238000010828 elution Methods 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 238000013265 extended release Methods 0.000 claims 4
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 4
- 229960001410 hydromorphone Drugs 0.000 claims 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 4
- 238000005336 cracking Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- JMBRWJAVUIITGV-LNNMZZBZSA-N hydrocodone bitartrate Chemical compound [H+].[H+].[H+].[H+].O.O.O.O.O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC JMBRWJAVUIITGV-LNNMZZBZSA-N 0.000 claims 3
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 claims 2
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 claims 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 2
- LIHDYIAAKPQZSN-UHFFFAOYSA-N 2,5-dihydroxy-5-methyl-3-(morpholin-4-ylamino)cyclopent-2-en-1-one Chemical compound O=C1C(C)(O)CC(NN2CCOCC2)=C1O LIHDYIAAKPQZSN-UHFFFAOYSA-N 0.000 claims 2
- IYNWSQDZXMGGGI-NUEKZKHPSA-N 3-hydroxymorphinan Chemical compound C1CCC[C@H]2[C@H]3CC4=CC=C(O)C=C4[C@]21CCN3 IYNWSQDZXMGGGI-NUEKZKHPSA-N 0.000 claims 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 2
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims 2
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims 2
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 claims 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 2
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 2
- 239000008896 Opium Substances 0.000 claims 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 2
- 229960001391 alfentanil Drugs 0.000 claims 2
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 2
- 229960001736 buprenorphine Drugs 0.000 claims 2
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 2
- 229960001113 butorphanol Drugs 0.000 claims 2
- 229960004126 codeine Drugs 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims 2
- 229950003851 desomorphine Drugs 0.000 claims 2
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 claims 2
- 229960003701 dextromoramide Drugs 0.000 claims 2
- 229960004193 dextropropoxyphene Drugs 0.000 claims 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 2
- 229960003461 dezocine Drugs 0.000 claims 2
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 2
- 229960000920 dihydrocodeine Drugs 0.000 claims 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 2
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 claims 2
- SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 claims 2
- 229960002500 dipipanone Drugs 0.000 claims 2
- 238000007907 direct compression Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 claims 2
- 229950010920 eptazocine Drugs 0.000 claims 2
- 229960004578 ethylmorphine Drugs 0.000 claims 2
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 claims 2
- 229950004155 etorphine Drugs 0.000 claims 2
- 229960002428 fentanyl Drugs 0.000 claims 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 238000007373 indentation Methods 0.000 claims 2
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 claims 2
- 229950009272 isomethadone Drugs 0.000 claims 2
- 229960003029 ketobemidone Drugs 0.000 claims 2
- 229960003406 levorphanol Drugs 0.000 claims 2
- IMYHGORQCPYVBZ-UHFFFAOYSA-N lofentanyl Chemical group C1CN(CCC=2C=CC=CC=2)CC(C)C1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 IMYHGORQCPYVBZ-UHFFFAOYSA-N 0.000 claims 2
- 229960000365 meptazinol Drugs 0.000 claims 2
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims 2
- 229960001797 methadone Drugs 0.000 claims 2
- 229960005181 morphine Drugs 0.000 claims 2
- 238000000465 moulding Methods 0.000 claims 2
- 229960004300 nicomorphine Drugs 0.000 claims 2
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims 2
- 229950011519 norlevorphanol Drugs 0.000 claims 2
- 229960004013 normethadone Drugs 0.000 claims 2
- WCJFBSYALHQBSK-UHFFFAOYSA-N normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 claims 2
- 229950007418 norpipanone Drugs 0.000 claims 2
- WCDSHELZWCOTMI-UHFFFAOYSA-N norpipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CCN1CCCCC1 WCDSHELZWCOTMI-UHFFFAOYSA-N 0.000 claims 2
- 229940005483 opioid analgesics Drugs 0.000 claims 2
- 229960001027 opium Drugs 0.000 claims 2
- 229960002085 oxycodone Drugs 0.000 claims 2
- 229960005118 oxymorphone Drugs 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 2
- 229960005301 pentazocine Drugs 0.000 claims 2
- 229960000482 pethidine Drugs 0.000 claims 2
- LOXCOAXRHYDLOW-UHFFFAOYSA-N phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 claims 2
- 229950004540 phenadoxone Drugs 0.000 claims 2
- CFBQYWXPZVQQTN-QPTUXGOLSA-N phenomorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CCC1=CC=CC=C1 CFBQYWXPZVQQTN-QPTUXGOLSA-N 0.000 claims 2
- 229950011496 phenomorphan Drugs 0.000 claims 2
- 229960004315 phenoperidine Drugs 0.000 claims 2
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- XJKQCILVUHXVIQ-UHFFFAOYSA-N properidine Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCN(C)CC1 XJKQCILVUHXVIQ-UHFFFAOYSA-N 0.000 claims 2
- 229950004345 properidine Drugs 0.000 claims 2
- 229960004739 sufentanil Drugs 0.000 claims 2
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 2
- 229960004380 tramadol Drugs 0.000 claims 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467824P | 2011-03-25 | 2011-03-25 | |
| US61/467,824 | 2011-03-25 | ||
| PCT/IB2012/000595 WO2012131463A2 (en) | 2011-03-25 | 2012-03-22 | Controlled release pharmaceutical dosage forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510094A JP2014510094A (ja) | 2014-04-24 |
| JP2014510094A5 true JP2014510094A5 (enExample) | 2014-12-04 |
| JP5964940B2 JP5964940B2 (ja) | 2016-08-03 |
Family
ID=46018006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014500486A Active JP5964940B2 (ja) | 2011-03-25 | 2012-03-22 | 制御放出性医薬剤形 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20140056979A1 (enExample) |
| EP (1) | EP2688556B1 (enExample) |
| JP (1) | JP5964940B2 (enExample) |
| KR (1) | KR101619579B1 (enExample) |
| CN (1) | CN103547259A (enExample) |
| AU (1) | AU2012235878B2 (enExample) |
| BR (1) | BR112013024585A8 (enExample) |
| CA (1) | CA2831218C (enExample) |
| CY (1) | CY1116579T1 (enExample) |
| DK (1) | DK2688556T3 (enExample) |
| ES (1) | ES2544735T3 (enExample) |
| HR (1) | HRP20150835T1 (enExample) |
| HU (1) | HUE026981T2 (enExample) |
| IL (1) | IL228441B (enExample) |
| ME (1) | ME02189B (enExample) |
| MX (1) | MX350875B (enExample) |
| PH (1) | PH12013501994A1 (enExample) |
| PL (1) | PL2688556T3 (enExample) |
| PT (1) | PT2688556E (enExample) |
| RS (1) | RS54152B1 (enExample) |
| SI (1) | SI2688556T1 (enExample) |
| SM (1) | SMT201500209B (enExample) |
| WO (1) | WO2012131463A2 (enExample) |
| ZA (1) | ZA201307862B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| EP2295043A1 (en) | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| AU2002227383B2 (en) | 2000-10-30 | 2004-07-08 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
| AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
| PL2826467T3 (pl) | 2010-12-22 | 2018-01-31 | Purdue Pharma Lp | Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| ES2716570T3 (es) | 2012-04-17 | 2019-06-13 | Purdue Pharma Lp | Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides |
| JP2015521988A (ja) | 2012-07-06 | 2015-08-03 | イガレット・リミテッド | 制御放出用乱用防止性医薬組成物 |
| PE20151301A1 (es) | 2013-02-05 | 2015-09-16 | Purdue Pharma Lp | Formulaciones farmaceuticas resistentes a la manipulacion indebida |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
| JP2020526500A (ja) | 2017-06-30 | 2020-08-31 | パーデュー、ファーマ、リミテッド、パートナーシップ | 治療方法及びその剤形 |
| JP7335870B2 (ja) * | 2017-08-31 | 2023-08-30 | パーデュー、ファーマ、リミテッド、パートナーシップ | 医薬剤形 |
| US12161754B2 (en) | 2017-12-20 | 2024-12-10 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950007907B1 (ko) * | 1992-09-01 | 1995-07-21 | 동국제약 주식회사 | 치주질환 치료용 막형 국소약물송달제제 |
| US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
| US5634702A (en) | 1995-09-27 | 1997-06-03 | Fistonich; Juraj | Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure |
| MXPA02007254A (es) * | 2000-02-04 | 2002-12-09 | Depomed Inc | Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero. |
| AU2002227383B2 (en) * | 2000-10-30 | 2004-07-08 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| CA2572491A1 (en) * | 2004-07-01 | 2006-01-12 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse |
| US7434308B2 (en) * | 2004-09-02 | 2008-10-14 | International Business Machines Corporation | Cooling of substrate using interposer channels |
| CN101232868A (zh) * | 2005-04-19 | 2008-07-30 | 阿尔扎公司 | 曲马多和加巴喷丁的控释递药剂型 |
| RU2008149702A (ru) * | 2006-05-17 | 2010-06-27 | Сандвик Интеллекчуал Проперти Аб (Se) | Верхнеударный инструмент для сверления камня, стержень сверла и соединительный рукав |
| SA07280459B1 (ar) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| WO2009012122A1 (en) * | 2007-07-13 | 2009-01-22 | Marvell World Trade Ltd. | Method for shallow trench isolation |
| WO2009114648A1 (en) * | 2008-03-11 | 2009-09-17 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| CN101933907A (zh) * | 2009-06-30 | 2011-01-05 | 北京天衡药物研究院 | 新型骨架缓释片及其制备方法 |
-
2012
- 2012-03-22 CN CN201280020303.9A patent/CN103547259A/zh active Pending
- 2012-03-22 HR HRP20150835TT patent/HRP20150835T1/hr unknown
- 2012-03-22 PH PH1/2013/501994A patent/PH12013501994A1/en unknown
- 2012-03-22 KR KR1020137027839A patent/KR101619579B1/ko active Active
- 2012-03-22 JP JP2014500486A patent/JP5964940B2/ja active Active
- 2012-03-22 MX MX2013010987A patent/MX350875B/es active IP Right Grant
- 2012-03-22 PL PL12717468T patent/PL2688556T3/pl unknown
- 2012-03-22 ES ES12717468.8T patent/ES2544735T3/es active Active
- 2012-03-22 PT PT127174688T patent/PT2688556E/pt unknown
- 2012-03-22 EP EP20120717468 patent/EP2688556B1/en active Active
- 2012-03-22 RS RS20150515A patent/RS54152B1/sr unknown
- 2012-03-22 HU HUE12717468A patent/HUE026981T2/en unknown
- 2012-03-22 SI SI201230275T patent/SI2688556T1/sl unknown
- 2012-03-22 US US14/004,857 patent/US20140056979A1/en not_active Abandoned
- 2012-03-22 ME MEP-2015-116A patent/ME02189B/me unknown
- 2012-03-22 AU AU2012235878A patent/AU2012235878B2/en active Active
- 2012-03-22 CA CA2831218A patent/CA2831218C/en active Active
- 2012-03-22 WO PCT/IB2012/000595 patent/WO2012131463A2/en not_active Ceased
- 2012-03-22 DK DK12717468.8T patent/DK2688556T3/en active
- 2012-03-22 BR BR112013024585A patent/BR112013024585A8/pt not_active Application Discontinuation
-
2013
- 2013-09-15 IL IL228441A patent/IL228441B/en active IP Right Grant
- 2013-10-22 ZA ZA2013/07862A patent/ZA201307862B/en unknown
-
2015
- 2015-08-03 CY CY20151100677T patent/CY1116579T1/el unknown
- 2015-09-09 SM SM201500209T patent/SMT201500209B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150835T1 (hr) | Farmaceutski oblici doziranja s kontroliranim oslobađanjem | |
| CA2913368C (en) | Abuse deterrent immediate release formulation | |
| CA2659523C (en) | Multilayer orally disintegrating tablet | |
| CA2661573A1 (en) | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic | |
| JP2006524249A5 (enExample) | ||
| US20150005334A1 (en) | Abuse deterrent compositions and methods of use | |
| JP2009545561A5 (enExample) | ||
| JP2010501543A5 (enExample) | ||
| JP2015500273A5 (enExample) | ||
| JP2011519930A5 (enExample) | ||
| TW201811332A (zh) | 處理由類鴉片引起之不利的藥效動力反應之系統和方法 | |
| CA2652981A1 (en) | Robust sustained release formulations | |
| US11141414B2 (en) | Pharmaceutical compositions comprising a pH-dependent component and pH-raising agent | |
| JP2008528534A5 (enExample) | ||
| WO2009015734A2 (en) | Dosage form comprising immediate release naproxen and sustained release opioid analgesic | |
| HRP20141001T1 (hr) | Farmaceutski sferoidi | |
| JP2021500316A5 (enExample) | ||
| US10736874B1 (en) | Methods for treating pain associated with sickle cell disease | |
| EP2046300B1 (en) | Multilayer orally disintegrating tablet | |
| US11571390B2 (en) | Abuse deterrent compositions and methods of use | |
| JP2020536892A5 (enExample) | ||
| EP3193873A1 (en) | Orally administrable compositions and methods of deterring abuse by intranasal administration | |
| HK1128881B (en) | Multilayer orally disintegrating tablet |